

## ASX MEDIA RELEASE

21 February 2023

# On-Sale Cleansing Notice Under Section 708a(5)(E) Corporations Act

**Clarity Pharmaceuticals** (ASX: CU6) (“Clarity” or the “Company”), issued 591,289 fully paid ordinary shares as a result of the exercise of options with an exercise price of \$0.22 per share on 17 February 2023 (the “Shares”).

Clarity has issued the Shares without disclosure to investors under section 708(5) *Corporations Act 2001* (Cth) (“Corporations Act”).

For the purposes of section 708A(6) Corporations Act, Clarity advises that:

- (a) the Shares have been issued without disclosure to investors under Part 6D.2 Corporations Act;
- (b) this notice is given under section 708A(5)(e) Corporations Act;
- (c) as at the date of this notice, Clarity has complied with:
  - (i) the provisions of Chapter 2M Corporations Act as they apply to Clarity; and
  - (ii) sections 674 and 674A Corporations Act; and
- (d) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) Corporations Act to be disclosed under section 708A(6)(e) Corporations Act.

Signed for and on behalf of Clarity

Robert Vickery  
Company Secretary

*This announcement has been authorised for release by Dr Alan Taylor, Executive Chairman.*

### **For more information, please contact:**

Dr Alan Taylor  
**Executive Chairman**  
[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

### **About Clarity Pharmaceuticals**

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)